10046934Butterfly Indoor Air Quality System integration with Building Management SystemsClosedGrant for R&DInnovate UKThe unifying element for analysis of human health and wellbeing and environmental sustainability lies in the air that we breathe. Health and Sustainability have previously been conflicted in the built environment where we spend 90% of our lives, because the former requires maximised introduction of fresh air whereas the latter requires maximised recirculation of existing air. The scale of the problem is most prominently highlighted through the emergence of Sick Building Syndrome (SBS). 1/3rd of industrialised country building stock is prone to SBS (WHO). Numerous neurotoxic and carcinogenic pollutants concentrated in commercial buildings induce headaches, eye, nose and throat irritation, fatigue and difficulty concentrating, alongside respiratory and cardiovascular diseases. This is a worsening trend, potentially causing 4m deaths p.a. (International WELL Building Institute (IWBI)). Existing Indoor Air Quality (IAQ) monitors do not provide the required quality of information to allow the Building Management Services industry to make this an intelligent process. Existing monitors regularly claim this facility, but cannot demonstrate it sufficiently to allow their technology to be embedded within critical infrastructure systems. Butterfly is developing a suite of devices which measure IAQ to an unparalleled level of accuracy. We have a patented LaminAIR flow technology, which allows us to constantly measure free gas around the room preventing re-circulated or stagnant air corrupting results (an industry-wide limitation). Our precision is so good it uniquely enables early trend detection and allows issue resolution in advance. We have gained traction with market leaders regarding integration within their systems. This project is to develop bespoke connectivity and data infrastructure and then trial this at 6 locations within Imperial College London's city-centre campus (they will independently validate results). Mutual Letters-of-Intent with joint-technology development commitment have been exchanged, including undertakings with Blueair-Unilever Sweden, Halton Group Finland and Imperial College London where trials will be undertaken and validation established.